Abstract
Secretory diarrhea is a historically known serious health implication around the world which primarily originates through pathogenic microorganisms rather than immunological or genetical disorders. This review highlights infective mechanisms of non-inflammatory secretory diarrhea causing pathogens, known therapeutics and their efficacy against them. These non-inflammatory diarrheal pathogens breach cell barriers, induce inflammation, disrupt fluid secretion across the epithelium by alteration in ion transport by faulting cystic fibrosis transmembrane conductance regulator (CFTR), calcium activated chloride channels and ion exchanger functions. Currently, a variety of prevention strategies have been used to treat these symptoms like use of antibacterial drugs, vaccines, fluid and nutritional therapy, probiotics and prebiotics as adjuncts. In progression of the need for a therapy having quick physiological effects, withdrawing the symptoms with a wide and safe therapeutic index, newer antisecretory agents like potent inhibitors, agonists and herbal remedies are some of the interventions which have come into light through greater understanding of the mechanisms and molecular targets involved in intestinal fluid secretion. Although these therapies have their own pros and cons inside the host, the quest for new antisecretory agents has been a successful elucidation to reduce burden of diarrheal disease.
Similar content being viewed by others
References
WHO (2013) Global Health Observatory Data Repository [online], http://www.who.int/mediacentre/factsheets/fs330/en/. Accessed 29 July 2016
Feldman M, Friedman LS, Brandt LJ (2010) Sleisenger and Fordtran’s Gastrointestinal and Liver Disease 9th edn, vol 1. Saunders Elsevier, Philadelphia
Sellin JH (2000) Secretory diarrhea. Curr Treat Options Gastroenterol 3:15–23
Navaneethan U, Giannella RA (2008) Mechanisms of infectious diarrhea. Nat Clin Pract Gastroenterol Hepatol 5:637–647
Nataro JP, Kaper JB (1998) Diarrheagenic Escherichia coli. Clin Microbiol Rev 11:142–201
Croxen MA, Finlay BB (2010) Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 8:26–38
Gupta SK, Keck J, Ram PK, Crump JA, Miller MA, Mintz ED (2008) Part III. Analysis of data gaps pertaining to enterotoxigenic Escherichia coli infections in low and medium human development index countries, 1984–2005. Epidemiol Infect 136:721–738
Dubreuil JD (2008) Escherichia coli STb toxin and colibacillosis: knowing is half the battle. FEMS Microbiol Lett 278:137–145
Dickinson BL, Clements JD (1995) Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63:1617–1623
Sears CL, Kaper JB (1996) Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbiol Rev 60:167
Streatfield SJ, Sandkvist M, Sixma TK, Bagdasarian M, Hol WG, Hirst TR (1992) Intermolecular interactions between the A and B subunits of heat-labile enterotoxin from Escherichia coli promote holotoxin assembly and stability in vivo. Proc Natl Acad Sci USA 89:12140–12144
Teneberg S, Hirst TR, Ngstrom J, Karlsson K-A (1994) Comparison of the glycolipid-binding specificities of cholera toxin and porcine Escherichia coli heat-labile enterotoxin: identification of a receptor-active non-ganglioside glycolipid for the heat-labile toxin in infant rabbit small intestine. Glycoconj J 11:533–540
Kesty NC, Mason KM, Reedy M, Miller SE, Kuehn MJ (2004) Enterotoxigenic Escherichia coli vesicles target toxin delivery into mammalian cells. EMBO J 23:4538–4549
Lencer WI, Constable C, Moe S, Jobling MG, Webb HM, Ruston S, Madara JL, Hirst TR, Holmes RK (1995) Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL. J Cell Biol 131:951–962
Hug MJ, Tamada T, Bridges RJ (2003) CFTR and bicarbonate secretion to epithelial cells. Physiology 18:38–42
Vaandrager AB, Tilly BC, Smolenski A, Schneider-Rasp S, Bot AG, Edixhoven M, Scholte BJ, Jarchau T, Walter U, Lohmann SM et al (1997) cGMP stimulation of cystic fibrosis transmembrane conductance regulator Cl- channels co-expressed with cGMP-dependent protein kinase type II but not type Iβ. J Biol Chem 272:4195–4200
Eklund S, Brunsson I, Jodal M, Lundgren O (1987) Changes in cyclic 3′5′-adenosine monophosphate tissue concentration and net fluid transport in the cat’s small intestine elicited by cholera toxin, arachidonic acid, vasoactive intestinal polypeptide and 5-hydroxytryptamine. Acta Physiol Scand 129:115–125
Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V (1988) Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect Immun 56:1748–1753
Arriaga YL, Harville BA, Dreyfus LA (1995) Contribution of individual disulfide bonds to biological action of Escherichia coli heat-stable enterotoxin B. Infect Immun 63:4715–4720
Rasheed JK, Guzm’an-Verduzco LM, Kupersztoch YM (1990) Two precursors of the heat-stable enterotoxin of Escherichia coli: evidence of extracellular processing. Mol Microbiol 4:265–273
Dubreuil JD (2012) The whole Shebang: the gastrointestinal tract, Escherichia coli enterotoxins and secretion. Curr Issues Mol Biol 14:71–82
Crane JK, Oh JS (1997) Activation of host cell protein kinase C by enteropathogenic Escherichia coli. Infect Immun 65:3277–3285
Rousset E, Harel J, Dubreuil JD (1998) Sulfatide from the pig jejunum brush border epithelial cell surface is involved in binding of Escherichia coli enterotoxin b. Infect Immun 66:5650–5658
Fujii Y, Nomura T, Yamanaka H, Okamoto K (1997) Involvement of Ca(2+)-calmodulin-dependent protein kinase II in the intestinal secretory action of Escherichia coli heat-stable enterotoxin II. Microbiol Immunol 41:633–636
Peterson JW, Whipp SC (1995) Comparison of the mechanisms of action of cholera toxin and the heat-stable enterotoxins of Escherichia coli. Infect Immun 63:1452–1461
Levine MM, Prado V, Robins-Browne R, Lior H, Kaper JB, Moseley SL, Gicquelais K, Nataro JP, Vial P, Tall B (1988) Use of DNA probes and HEp-2 cell adherence assay to detect diarrheagenic Escherichia coli. J Infect Dis 158:224–228
Menard LP, Dubreuil JD (2002) Enteroaggregative Escherichia coli heat-stable enterotoxin 1 (EAST1): a new toxin with an old twist. Crit Rev Microbiol 28:43–60
Veilleux S, Dubreuil JD (2006) Presence of Escherichia coli carrying the EAST1 toxin gene in farm animals. Vet Res 37:3–13
Savarino SJ, Fasano A, Watson J, Martin BM, Levine MM, Guandalini S, Guerry P (1993) Enteroaggregative Escherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin. Proc Natl Acad Sci USA 90:3093–3097
Savarino SJ, McVeigh A, Watson J, Cravioto A, Molina J, Echeverria P, Bhan MK, Levine MM, Fasano A (1996) Enteroaggregative Escherichia coli heat-stable enterotoxin is not restricted to enteroaggregative E. coli. J Infect Dis 173:1019–1022
Huang DB, Okhuysen PC, Jiang ZD, DuPont HL (2004) Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol 99(2):383–389
Zhang R-G, Scott DL, Westbrook ML, Nance S, Spangler BD, Shipley GG, Westbrook EM (1995) The three-dimensional crystal structure of cholera toxin. J Mol Biol 251:563–573
Cheng SH, Rich DP, Marshall J, Gregory RJ, Welsh MJ, Smith AE (1991) Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 66:1027–1036
Guttman JA, Finlay BB (2008) Subcellular alterations that lead to diarrhea during bacterial pathogenesis. Trends Microbiol 16:535–542
Lundgren O, Jodal M (1997) The enteric nervous system and cholera toxin—induced secretion. Comp Biochem Physiol A Physiol 118:319–327
Trucksis M, Conn TL, Wasserman SS, Sears CL (2000) Vibrio cholerae ACE stimulates Ca2+−dependent Cl-/HCO3- secretion in T84 cells in vitro. Am J Physiol Cell Physiol 279:C567–C577
Krasilnikov OV, Muratkhodjaev JN, Zitzer AO (1992) The mode of action of Vibrio cholerae cytolysin. The influences on both erythrocytes and planar lipid bilayers. Biochim Biophys Acta 1111:7–16
Visweswariah SS, Shanthi G, Balganesh TS (1992) Interaction of heat-stable enterotoxins with human colonie (T84) cells: modulation of the activation of guanylyl cyclase. Microb Pathog 12:209–218
Wang W, Uzzau S, Goldblum SE, Fasano A (2000) Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci 113:4435–4440
Wu Z, Nybom P, Magnusson K-E (2000) Distinct effects of Vibrio cholerae haemagglutinin/protease on the structure and localization of the tight junction-associated proteins occludin and ZO-1. Cell Microbiol 2:11–17
Uzzau S, Cappuccinelli P, Fasano A (1999) Expression of Vibrio cholerae zonula occludens toxin and analysis of its subcellular localization. Microb Pathog 27:377–385
Hodges K, Gill R (2010) Infectious diarrhea: cellular and molecular mechanisms. Gut Microbes 1:4–21
Hodges K, Alto NM, Ramaswamy K, Dudeja PK, Hecht G (2008) The enteropathogenic Escherichia coli effector protein EspF decreases sodium hydrogen exchanger 3 activity. Cell Microbiol 10:1735–1745
Hecht G, Hodges K, Gill RK, Kear F, Tyagi S, Malakooti J, Ramaswamy K, Dudeja PK (2004) Differential regulation of Na+/H+ exchange isoform activities by enteropathogenic E. coli in human intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 287:G370–G378
Makela (2002) SLC26A3 mutations in congenital chloride diarrhea. Hum Mutat 20:425–438
Gill RK, Borthakur A, Hodges K, Turner JR, Clayburgh DR, Saksena S, Zaheer A, Ramaswamy K, Hecht G, Dudeja PK (2007) Mechanism underlying inhibition of intestinal apical Cl-- /OH--exchange following infection with enteropathogenic E. coli. J Clin Invest 117:428–437
Dean P, Maresca M, Schuller S, Phillips AD, Kenny B (2006) Potent diarrheagenic mechanism mediated by the cooperative action of three enteropathogenic Escherichia coli-injected effector proteins. Proc Natl Acad Sci USA 103:1876–1881
Borthakur A, Gill RK, Hodges K, Ramaswamy K, Hecht G, Dudeja PK (2006) Enteropathogenic Escherichia coli inhibits butyrate uptake in Caco-2 cells by altering the apical membrane MCT1 level. Am J Physiol Gastrointest Liver Physiol 290:G30–G35
Gill RK, Saksena S, Tyagi S, Alrefai WA, Malakooti J, Sarwar Z, Turner JR, Ramaswamy K, Dudeja PK (2005) Serotonin inhibits Na+/H+ exchange activity via 5-HT4 receptors and activation of PKC in human intestinal epithelial cells. Gastroenterology 128:962–974
Blacklow NR, Greenberg HB (1991) Viral gastroenteritis. N Engl J Med 325:252–264
Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD et al (2012) 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 12:136–141
Sen A, Rott L, Phan N, Mukherjee G, Greenberg HB (2014) Rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation. J Virol 88:41–53
Lorrot M, Vasseur M (2007) Physiopathology of Rotavirus diarrhea. Arch Pediatr 14:S145–51
Halaihel N, Li’evin V, Alvarado F, Vasseur M (2000) Rotavirus infection impairs intestinal brush-border membrane Na+−solute cotransport activities in young rabbits. Am J Physiol Gastrointest Liver Physiol 279:G587–G596
Jourdan N, Brunet JP, Sapin C, Blais A, Cotte-Laffitte J, Forestier F, Quero A-M, Trugnan G, Servin AL (1998) Rotavirus infection reduces sucrase-isomaltase expression in human intestinal epithelial cells by perturbing protein targeting and organization of microvillar cytoskeleton. J Virol 72:7228–7236
Estes MK, Prasad BV, Atmar RL (2006) Noroviruses everywhere: has something changed? Curr Opin Infect Dis 19:467–474
Javier B, Rodriguez-Diaz J (2006) Molecular virology of enteric viruses (with emphasis on caliciviruses). In: Viruses in Foods. Springer, pp 43–100
Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, Jiang X (2005) Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 79:6714–6722
Kuyumcu-Martinez M, Belliot G, Sosnovtsev SV, Chang KO, Green KY, Lloyd RE (2004) Calicivirus 3C-like proteinase inhibits cellular translation by cleavage of poly (A)-binding protein. J Virol 78:8172–8182
Ettayebi K, Hardy ME (2003) Norwalk virus nonstructural protein p48 forms a complex with the SNARE regulator VAP-A and prevents cell surface expression of vesicular stomatitis virus G protein. J Virol 77:11790–11797
Troeger H, Loddenkemper C, Schneider T, Schreier E, Epple H-J, Zeitz M, Fromm M, Schulzke JD (2009) Structural and functional changes of the duodenum in human norovirus infection. Gut 58:1070–1077
Muller N, Von Allmen N (2005) Recent insights into the mucosal reactions associated with Giardia lamblia infections. Int J Parasitol 35:1339–1347
Buret A, Hardin JA, Olson ME, Gall DG (1992) Pathophysiology of small intestinal malabsorption in gerbils infected with Giardia lamblia. Gastroenterology 103:506–13
Resta-Lenert S, Langford TD, Gillin FD, Barrett KE (2000) Altered chloride secretory responses in HT29/Cl. 19A cells infected with Giardia lamblia. Gastroenterology 118:A684
Gorowara S, Ganguly NK, Mahajan RC, Walia BN (1992) Study on the mechanism of Giardia lambdia induced diarrhoea in mice. BBA Mol Basis Dis 1138:122–126
Buret AG (2007) Mechanisms of epithelial dysfunction in giardiasis. Gut 56:316–317
Chin AC, Teoh DA, Scott KGE, Meddings JB, Macnaughton WK, Buret AG (2002) Strain-dependent induction of enterocyte apoptosis by Giardia lamblia disrupts epithelial barrier function in a caspase-3-dependent manner. Infect Immun 70:3673–3680
DuPont HL (2009) Bacterial diarrhea. N Engl J Med 361:1560–1569
Wagner A, Wiedermann U (2009) Travellers’ diarrhoea—pros and cons of different prophylactic measures. Wien Klin Wochenschr 121:13–18
Rademaker C, Hoepelman IM, Wolfhagen M, Beumer H, Rozenberg-Arska M, Verhoef J (1989) Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers’ diarrhea. Eur J Clin Microbiol Infect Dis 8:690–694
Wistrom J, Norrby SR, Burman LG, Lundholm R, Jellheden B, Englund G (1987) Norfloxacin versus placebo for prophylaxis against travellers’ diarrhoea. J Antimicrob Chemother 20:563–574
Johnson PC, Ericsson CD, Morgan DR, DuPont HL, Cabada FJ (1986) Lack of emergence of resistant fecal flora during successful prophylaxis of traveler’s diarrhea with norfloxacin. Antimicrob Agents Chemother 30:671–674
Mehlhorn AJ, Brown DA (2007) Safety concerns with fluoroquinolones. Ann Pharmacother 41:1859–1866
Ruiz J, Mensa L, O’Callaghan C, Pons MJ, Gonz’alez A, Vila J, Gasc’on J (2007) In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler’s diarrhea. Diagn Microbiol Infect Dis 59:473–475
Fuller JD, Low DE (2005) A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 41:118–121
Nelson JM, Smith KE, Vugia DJ, Rabatsky-Ehr T, Segler SD, Kassenborg HD, Zansky SM, Joyce K, Marano N, Hoekstra RM et al (2004) Prolonged diarrhea due to ciprofloxacin-resistant Campylobacter infection. J Infect Dis 190:1150–1157
Isenbarger DW, Hoge CW, Srijan A, Pitarangsi C, Vithayasai N, Bodhidatta L, Hickey KW, Cam PD (2002) Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996–1999. Emerg Infect Dis 8:175–180
Ericsson CD (2005) Nonantimicrobial agents in the prevention and treatment of traveler’s diarrhea. Clin Infect Dis 41:S557–S563
DuPont HL, Ericsson CD, Johnson PC, Bitsura JAM, DuPont MW, de la Cabada FJ (1987) Prevention of travelers’ diarrhea by the tablet formulation of bismuth subsalicylate. JAMA 257:1347–1350
DuPont HL, Jiang Z-D, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F (2005) A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 142:805–812
Chang L, Chey WD, Drossman DA, Lembo A, Pimentel M, Schoenfeld PS, Yu J, Merchant K, Paterson C, Bortey E, others (2012) Tu1403 Safety and tolerability profile of rifaximin for treatment of IBS without constipation: results of a pooled analysis of double-blind, placebo-controlled randomized controlled trials. Gastroenterology 142:S-823
Heel RC, Brogden RN, Speight TM, Avery GS (1978) Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 15:33–52
Van Loon FP, Bennish ML, Speelman P, Butler C (1989) Double blind trial of loperamide for treating acute watery diarrhoea in expatriates in Bangladesh. Gut 30:492–495
Menees S, Saad R, Chey WD (2012) Agents that act luminally to treat diarrhoea and constipation. Nat Rev Gastroenterol Hepatol 9:661–674
Tradtrantip L, Namkung W, Verkman AS (2010) Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol 77:69–78
Mangel AW, Chaturvedi P (2008) Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 78:180–186
Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy P, Stanton B, Huda N, Khan MU, Kay BA, Khan MR et al (1988) Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158:372–377
Torrell JMR, Aumatell CM, Ramos SM, Mestre LG, Salas CM (2009) Reduction of travellers’ diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers. Vaccine 27:4074–4077
Ahmed T, Bhuiyan TR, Zaman K, Sinclair D, Qadri F (2013) Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev 7, CD009029
Yu J, Cassels F, Scharton-Kersten T, Hammond SA, Hartman A, Angov E, Corth’esy B, Alving C, Glenn G (2002) Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli. Infect Immun 70:1056–1068
Frech SA, DuPont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez-Sandoval FG, Mel’endez-Romero JH, Jiang ZD, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN, Flyer DC, Andersen BH, Kazempour K, Breisch SA, Glenn GM (2008) Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase II, randomized, double-blind, placebo-controlled field trial. Lancet 371:2019–2025
Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HLE, Maxwell R, Paredes MP, Glenn GM, Dewasthaly S, Stablein DM, Jiang ZD, Dupont HL (2014) Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis 14:197–204
Roberto M, Mercedes P-P, Glenn GM, Shailesh D, Stablein DM, Zhi-Dong J, DuPont HL, Dennehy PH (2008) Rotavirus vaccines: an overview. Clin Microbiol Rev 21:198–208
Midthun K, Kapikian AZ (1996) Rotavirus vaccines: an overview. Clin Microbiol Rev 9:423–434
Peter G, Myers MG (2002) Intussusception, rotavirus, and oral vaccines: summary of a workshop. Pediatrics 110:e67
Rha B, Tate JE, Payne DC, Cortese MM, Lopman BA, Curns AT, Parashar UD (2014) Effectiveness and impact of rotavirus vaccines in the United States--2006--2012. Expert Rev Vaccines 13:365–376
Cortes JE, Curns AT, Tate JE, Cortese MM, Patel MM, Zhou F, Parashar UD (2011) Rotavirus vaccine and health care utilization for diarrhea in US children. N Engl J Med 365:1108–1117
Heaton PM, Ciarlet M (2007) The pentavalent rotavirus vaccine: discovery to licensure and beyond. Clin Infect Dis 45:1618–1624
Kirkwood CD (2010) Genetic and antigenic diversity of human rotaviruses: potential impact on vaccination programs. J Infect Dis 202:S43–S48
O’Ryan M, Linhares AC (2009) Update on Rotarix™: an oral human rotavirus vaccine. Expert Rev Vaccines 8:1627–1641
Wang C-M, Chen S-C, Chen K-T (2015) Current status of rotavirus vaccines. World J Pediatr 11:300–308
Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS et al (2014) Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 383:2136–2143
Casburn-Jones AC, Farthing M (2004) Management of infectious diarrhoea. Gut 53:296–305
International Study Group on Reduced-Osmolality ORS Solutions (1995) Multicentre evaluation of reduced-osmolality oral rehydration salts solution. Lancet 346:282–5
Thillainayagam AV, Hunt JB, Farthing MJ (1998) Enhancing clinical efficacy of oral rehydration therapy: is low osmolality the key? Gastroenterology 114:197–210
Czerwionka-Szaflarska M, Murawska S, Swincow G (2009) Evaluation of influence of oral treatment with probiotic and/or oral rehydration solution on course of acute diarrhoea in children. Prz Gastroenterol 4:166–U8
Passariello A, Terrin G, De Marco G, Cecere G, Ruotolo S, Marino A, Cosenza L, Tardi M, Nocerino R, Canani RB (2011) Efficacy of a new hypotonic oral rehydration solution containing zinc and prebiotics in the treatment of childhood acute diarrhea: a randomized controlled trial. J Pediatr 158:288–292
Oli MW, Petschow BW, Buddington RK (1998) Evaluation of fructooligosaccharide supplementation of oral electrolyte solutions for treatment of diarrhea (Recovery of the intestinal bacteria). Dig Dis Sci 43:138–147
FAO/WHO (2002) Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada, 30
Salminen S (2001) Human studies on probiotics: aspects of scientific documentation. Scand J Nutr 1:01
Guarino A, Albano F, Ashkenazi S, Gendrel D, Hoekstra JH, Shamir R, Szajewska H, ESPGHAN/ESPID Evidence-Based Guidelines for the Management of Acute Gastroenteritis in Children in Europe Expert working group (2008) European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: executive summary. J Pediatr Gastroenterol Nutr 46:619–621
Sanders ME, Guarner F, Guerrant R, Holt PR, Quigley EM, Sartor RB, Sherman PM, Mayer EA (2013) An update on the use and investigation of probiotics in health and disease. Gut 62:787–796
Allen SJ, Martinez EG, Gregorio GV, Dans LF (2010) Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 11, CD003048
McFarland LV (2007) Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis 5:97–105
Feizizadeh S, Salehi-Abargouei A, Akbari V (2014) Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics 134:e176–e191
Zhang Y, Zhang L, Du M, Yi H, Guo C, Tuo Y, Han X, Li J, Zhang L, Yang L (2011) Antimicrobial activity against Shigella sonnei and probiotic properties of wild lactobacilli from fermented food. Microbiol Res 167:27–31
Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J (2008) Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14:166–171
Ogawa M, Shimizu K, Nomoto K, Tanaka R, Hamabata T, Yamasaki S, Takeda T, Takeda Y (2001) Inhibition of in vitro growth of Shiga toxin-producing Escherichia coli O157: H7 by probiotic Lactobacillus strains due to production of lactic acid. Int J Food Microbiol 68:135–140
Lievin-Le Moal V, Amsellem R, Servin AL, Coconnier MH (2002) Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells. Gut 50:803–811
Coconnier M-H, Li’evin V, Bernet-Camard M-F, Hudault S, Servin AL (1997) Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB. Antimicrob Agents Chemother 41:1046–1052
Silva M, Jacobus NV, Deneke C, Gorbach SL (1987) Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 31:1231–1233
Colb’ere-Garapin F, Martin-Latil S, Blondel B, Mousson L, Pelletier I, Autret A, Francois A, Niborski V, Grompone G, Catonnet G et al (2007) Prevention and treatment of enteric viral infections: possible benefits of probiotic bacteria. Microb Infect 9:1623–1631
Sassone-Corsi M, Raffatellu M (2015) No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. J Immunol 194:4081–4087
Makras L, Triantafyllou V, Fayol-Messaoudi D, Adriany T, Zoumpopoulou G, Tsakalidou E, Servin A, De Vuyst L (2006) Kinetic analysis of the antibacterial activity of probiotic lactobacilli towards Salmonella enterica serovar Typhimurium reveals a role for lactic acid and other inhibitory compounds. Res Microbiol 157:241–247
Collado MC, Hern’andez M, Sanz Y (2005) Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains. J Food Protect 68:1034–1040
Bevins CL, Salzman NH (2011) Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 9:356–368
Melo MN, Ferre R, Castanho MA (2009) Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat Rev Microbiol 7:245–250
Lu R, Fasano S, Madayiputhiya N, Morin NP, Nataro J, Fasano A (2009) Isolation, identification, and characterization of small bioactive peptides from Lactobacillus GG conditional media that exert both anti-Gram-negative and Gram-positive bactericidal activity. J Pediatr Gastroenterol Nutr 49:23–30
Fayol-Messaoudi D, Berger CN, Coconnier-Polter M-H, Lievin-Le Moal V, Servin AL (2005) pH-, Lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol 71:6008–6013
Pridmore RD, Pittet A-C, Praplan F, Cavadini C (2008) Hydrogen peroxide production by Lactobacillus johnsonii NCC 533 and its role in anti-Salmonella activity. FEMS Microbiol Lett 283:210–215
Coyne CB, Bergelson JM (2006) Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124:119–131
Rossen JW, Bouma J, Raatgeep RH, Buller HA, Einerhand AW (2004) Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step. J Virol 78:9721–9730
Freitas M, Tavan E, Cayuela C, Diop L, Sapin C, Trugnan G (2003) Host-pathogens cross-talk. Indigenous bacteria and probiotics also play the game. Biol Cell 95:503–506
Guti’errez S, Mart’nez-Blanco H, Rodr’guez-Aparicio LB, Ferrero MA (2016) Effect of fermented broth from lactic acid bacteria on pathogenic bacteria proliferation. J Dairy Sci 99(4):2654–65
Gueimonde M, Margolles A, Clara G, Salminen S (2007) Competitive exclusion of enteropathogens from human intestinal mucus by Bifidobacterium strains with acquired resistance to bile—A preliminary study. Int J Food Microbiol 113:228–232
Collado MC, Meriluoto J, Salminen S (2008) Adhesion and aggregation properties of probiotic and pathogen strains. Eur Food Res Technol 226:1065–1073
Lee Y-K, Puong K-Y, Ouwehand AC, Salminen S (2003) Displacement of bacterial pathogens from mucus and Caco-2 cell surface by lactobacilli. J Med Microbiol 52:925–930
Servin AL, Coconnier M-H (2003) Adhesion of probiotic strains to the intestinal mucosa and interaction with pathogens. Best Pract Res Clin Gastroenterol 17:741–754
McGuckin MA, Lind’en SK, Sutton P, Florin TH (2011) Mucin dynamics and enteric pathogens. Nat Rev Microbiol 9:265–278
Dhanani AS, Bagchi T (2013) The expression of adhesin EF-Tu in response to mucin and its role in Lactobacillus adhesion and competitive inhibition of enteropathogens to mucin. J Appl Microbiol 115:546–554
Kankainen M, Paulin L, Tynkkynen S, von Ossowski I, Reunanen J, Partanen P, Satokari R, Vesterlund S, Hendrickx AP, Lebeer S et al (2009) Comparative genomic analysis of Lactobacillus rhamnosus GG reveals pili containing a human-mucus binding protein. Proc Natl Acad Sci USA 106:17193–17198
van Pijkeren J-P, Canchaya C, Ryan KA, Li Y, Claesson MJ, Sheil B, Steidler L, O’Mahony L, Fitzgerald GF, van Sinderen D et al (2006) Comparative and functional analysis of sortase-dependent proteins in the predicted secretome of Lactobacillus salivarius UCC118. Appl Environ Microbiol 72:4143–4153
Altermann E, Russell WM, Azcarate-Peril MA, Barrangou R, Buck BL, McAuliffe O, Souther N, Dobson A, Duong T, Callanan M et al (2005) Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci USA 102:3906–3912
Buck BL, Altermann E, Svingerud T, Klaenhammer TR (2005) Functional analysis of putative adhesion factors in Lactobacillus acidophilus NCFM. Appl Environ Microbiol 71:8344–8351
Pretzer G, Snel J, Molenaar D, Wiersma A, Bron PA, Lambert J, de Vos WM, van der Meer R, Smits MA, Kleerebezem M (2005) Biodiversity-based identification and functional characterization of the mannose-specific adhesin of Lactobacillus plantarum. J Bacteriol 187:6128–6136
Pridmore RD, Berger B, Desiere F, Vilanova D, Barretto C, Pittet A-C, Zwahlen M-C, Rouvet M, Altermann E, Barrangou R et al (2004) The genome sequence of the probiotic intestinal bacterium Lactobacillus johnsonii NCC 533. Proc Natl Acad Sci USA 101:2512–2517
Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA (1999) Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol Gastrointest Liver Physiol 276:G941–G950
Bruce AW, Reid G (1988) Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections. Can J Microbiol 34:339–343
Chan RC, Reid G, Irvin RT, Bruce AW, Costerton JW (1985) Competitive exclusion of uropathogens from human uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infect Immun 47:84–89
Reid G, Chan RC, Bruce AW, Costerton JW (1985) Prevention of urinary tract infection in rats with an indigenous Lactobacillus casei strain. Infect Immun 49:320–324
Bernet M-F, Brassart D, Neeser JR, Servin AL (1993) Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol 59:4121–4128
Lievin V, Peiffer I, Hudault S, Rochat F, Brassart D, Neeser JR, Servin AL (2000) Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 47:646–652
P’erez PF, Minnaard J, Rouvet M, Knabenhans C, Brassart D, De Antoni GL, Schiffrin EJ (2001) Inhibition of Giardia intestinalis by Extracellular Factors from Lactobacilli: an in vitro Study. Appl Environ Microbiol 67:5037–5042
Brocklehurst TF, Lund BM (1990) The influence of pH, temperature and organic acids on the initiation of growth of Yersinia enterocolitica. J Appl Microbiol 69:390–397
Carey CM, Kostrzynska M, Ojha S, Thompson S (2008) The effect of probiotics and organic acids on Shiga-toxin 2 gene expression in enterohemorrhagic Escherichia coli O157: H7. J Microbiol Meth 73:125–132
Medellin-Pena MJ, Wang H, Johnson R, Anand S, Griffiths MW (2007) Probiotics affect virulence-related gene expression in Escherichia coli O157: H7. Appl Environ Microbiol 73:4259–4267
Hecht G (2001) Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VII. Enteropathogenic Escherichia coli: physiological alterations from an extracellular position. Am J Physiol Gastrointest Liver Physiol 281:G1–7
Klingberg TD, Pedersen MH, Cencic A, Budde BB (2005) Application of measurements of transepithelial electrical resistance of intestinal epithelial cell monolayers to evaluate probiotic activity. Appl Environ Microbiol 71:7528–7530
Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P (2000) Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 68:5998–6004
Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T et al (2011) Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469:543–547
Lenoir-Wijnkoop I, Sanders ME, Cabana MD, Caglar E, Corthier G, Rayes N, Sherman PM, Timmerman HM, Vaneechoutte M, Van Loo J et al (2007) Probiotic and prebiotic influence beyond the intestinal tract. Nutr Rev 65:469–489
Gibson GR, McCartney AL, Rastall RA (2005) Prebiotics and resistance to gastrointestinal infections. Br J Nutr 93:S31–S34
Topping DL, Fukushima M, Bird AR (2003) Resistant starch as a prebiotic and synbiotic: state of the art. Proc Nutr Soc 62:171–176
Scheppach W, Luehrs H, Menzel T (2001) Beneficial health effects of low-digestible carbohydrate consumption. Br J Nutr 85:S23–S30
Likotrafiti E, Tuohy KM, Gibson GR, Rastall RA (2013) Development of antimicrobial synbiotics using potentially-probiotic faecal isolates of Lactobacillus fermentum and Bifidobacterium longum. Anaerobe 20:5–13
Saran S, Bisht MS, Singh K, Teotia U (2012) Comparing adhesion attributes of two isolates of Lactobacillus acidophilus for assessment of prebiotics, honey and inulin. IJSRP 2:2250–3153
Shoaf-Sweeney KD, Hutkins RW (2008) Adherence, anti-adherence, and oligosaccharides: preventing pathogens from sticking to the host. Adv Food Nutr Res 55:101–161
Bode L (2012) Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22:1147–1162
Kunz C, Rudloff S, Baier W, Klein N, Strobel S (2000) Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr 20:699–722
Shoaf K, Mulvey GL, Armstrong GD, Hutkins RW (2006) Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infect Immun 74:6920–6928
Peshev D, Van den Ende W (2014) Fructans: prebiotics and immunomodulators. J Funct Foods 8:348–357
Capitan-Canadas F, Ortega-Gonzalez M, Guadix E, Zarzuelo A, Suarez MD, Medina FS, Martinez-Augustin O (2014) Prebiotic oligosaccharides directly modulate proinflammatory cytokine production in monocytes via activation of TLR4. Mol Nutr Food Res 58:1098–1110
Vanmaele RP, Heerze LD, Armstrong GD (1999) Role of lactosyl glycan sequences in inhibiting enteropathogenic Escherichia coli attachment. Infect Immun 67:3302–3307
Knutton S, Adu-Bobie J, Bain C, Phillips AD, Dougan G, Frankel G (1997) Down regulation of intimin expression during attaching and effacing enteropathogenic Escherichia coli adhesion. Infect Immun 65:1644–1652
Drakoularakou A, Tzortzis G, Rastall RA, Gibson GR (2010) A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers’ diarrhoea. Eur J Clin Nutr 64:146–152
Bruzzese E, Volpicelli M, Squeglia V, Bruzzese D, Salvini F, Bisceglia M, Lionetti P, Cinquetti M, Iacono G, Amarri S et al (2009) A formula containing galacto-and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. Clin Nutr 28:156–161
Arslanoglu S, Moro GE, Schmitt J, Tandoi L, Rizzardi S, Boehm G (2008) Early dietary intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic manifestations and infections during the first two years of life. J Nutr 138:1091–1095
Arslanoglu S, Moro GE, Boehm G (2007) Early supplementation of prebiotic oligosaccharides protects formula-fed infants against infections during the first 6 months of life. J Nutr 137:2420–2424
Waligora-Dupriet A-J, Campeotto F, Nicolis I, Bonet A, Soulaines P, Dupont C, Butel M-J (2007) Effect of oligofructose supplementation on gut microflora and well-being in young children attending a day care centre. Int J Food Microbiol 113:108–113
Cummings JH, Christie S, Cole TJ (2001) A study of fructo oligosaccharides in the prevention of travellers’ diarrhoea. Aliment Pharmacol Ther 15:1139–1145
Saavedra J, Tschernia A, Moore N, Abi-Hanna A, Coletta F, Emenhiser C, Yolken R (1999) Gastro-intestinal function in infants consuming a weaning food supplemented with oligofructose, a prebiotic. J Pediatr Gastroenterol Nutr 29:513
Tschernia A, Moore N, Abi-Hanna A, Yolken R, Coletta F, Emenhiser C, Saavedra J (1999) Effects of long-term consumption of a weaning food supplemented with oligofructose, a prebiotic, on general infant health status. J Pediatr Gastroenterol Nutr 29:503
Pariwat P, Homvisasevongsa S, Muanprasat C, Chatsudthipong V (2008) A natural plant-derived dihydroisosteviol prevents cholera toxin-induced intestinal fluid secretion. J Pharmacol Exp Ther 324:798–805
Palombo EA (2006) Phytochemicals from traditional medicinal plants used in the treatment of diarrhoea: modes of action and effects on intestinal function. Phytother Res 20:717–724
Dubreuil JD (2013) Antibacterial and antidiarrheal activities of plant products against enterotoxinogenic Escherichia coli. Toxins 5(11):2009–2041
Cui H-H, Chen C-L, Wang JD, Yang Y-J, Cun Y, Wu J-B, Liu YH, Dan H-L, Jian Y-T, Chen X-Q (2004) Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 10:1521–1525
Lin H-C, Su B-H, Chen A-C, Lin T-W, Tsai C-H, Yeh T-F, Oh W (2005) Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 115:1–4
Ruszczy’nski M, Radzikowski A, Szajewska H (2008) Clinical trial: effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. Aliment Pharmacol Ther 28:154–161
Paton AW, Morona R, Paton JC (2006) Designer probiotics for prevention of enteric infections. Nat Rev Microbiol 4:193–200
Paton AW, Morona R, Paton JC (2010) Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections. Bioeng Bugs 1:172–177
Paton AW, Morona R, Paton JC (2000) A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 6:265–270
Paton AW, Jennings MP, Morona R, Wang H, Focareta A, Roddam LF, Paton JC (2005) Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 128:1219–1228
Focareta A, Paton JC, Morona R, Cook J, Paton AW (2006) A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 130:1688–1695
Sheehan VM, Sleator RD, Hill C, Fitzgerald GF (2007) Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology 153:3563–3571
Sleator RD, Hill C (2007) Patho-biotechnology; using bad bugs to make good bugs better. Sci Prog 90:1–14
Kimman TG, Smit E, Klein MR (2008) Evidence-based biosafety: a review of the principles and effectiveness of microbiological containment measures. Clin Microbiol Rev 21:403–425
Liu HY, Roos S, Jonsson H, Ahl D, Dicksved J, Lindberg JE, Lundh T (2015) Effects of Lactobacillus johnsonii and Lactobacillus reuteri on gut barrier function and heat shock proteins in intestinal porcine epithelial cells. Physiol Rep 3, e12355
Tuomola EM, Ouwehand AC, Salminen SJ (1999) The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunol Med Microbiol 26:137–142
Nandakumar NS, Pugazhendhi S, Madhu Mohan K, Jayakanthan K, Ramakrishna BS (2009) Effect of Vibrio cholerae on chemokine gene expression in HT29 cells and its modulation by Lactobacillus GG. Scand J Immunol 69:181–187
Chauviere G, Coconnier M-H, Kern’eis S, Fourniat J, Servin AL (1992) Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. Microbiology 138:1689–1696
Munoz JAM, Chenoll E, Casinos B, Bataller E, Ram’on D, Genov’es S, Montava R, Ribes JM, Buesa J, F’abrega J et al (2011) Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl Environ Microbiol 77:8775–8783
Zanello G, Meurens F, Berri M, Chevaleyre C, Melo S, Auclair E, Salmon H (2011) Saccharomyces cerevisiae decreases inflammatory responses induced by F4+ enterotoxigenic Escherichia coli in porcine intestinal epithelial cells. Vet Immunol Immunopathol 141:133–138
Lodemann U, Strahlendorf J, Schierack P, Klingspor S, Aschenbach JR, Martens H (2015) Effects of the probiotic Enterococcus faecium and pathogenic Escherichia coli strains in a pig and human epithelial intestinal cell model. Scientifica 2015:235184
Gopal PK, Prasad J, Smart J, Gill HS (2001) In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int J Food Microbiol 67:207–216
Varyukhina S, Freitas M, Bardin S, Robillard E, Tavan E, Sapin C, Grill J-P, Trugnan G (2012) Glycan-modifying bacteria-derived soluble factors from Bacteroides thetaiotaomicron and Lactobacillus casei inhibit rotavirus infection in human intestinal cells. Microb Infect 14:273–278
Roselli M, Finamore A, Britti MS, Mengheri E (2006) Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr 95:1177–1184
Michail S, Abernathy F (2002) Lactobacillus plantarum reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic Escherichia coli infection. J Pediatr Gastroenterol Nutr 35:350–355
Lee DK, Park JE, Kim MJ, Seo JG, Lee JH, Ha NJ (2015) Probiotic bacteria. B. longum and L. acidophilus inhibit infection by rotavirus in vitro and decrease the duration of diarrhea in pediatric patients. Clin Res Hepatol Gastroenterol 39:237–244
Fourniat J, Djaballi Z, Maccario J, Bourlioux P, German A (1986) Effect of killed Lactobacillus acidophilus administration on the survival of suckling mice infected with an enterotoxigenic Escherichia coli. Ann Rech Vet 17:401–407
Zhang L, Xu Y-Q, Liu HY, Lai T, Ma J-L, Wang J-F, Zhu Y-H (2010) Evaluation of Lactobacillus rhamnosus GG using an Escherichia coli K88 model of piglet diarrhoea: Effects on diarrhoea incidence, faecal microflora and immune responses. Vet Microbiol 141:142–148
Preidis GA, Saulnier DM, Blutt SE, Mistretta T-A, Riehle KP, Major AM, Venable SF, Barrish JP, Finegold MJ, Petrosino JF et al (2012) Host response to probiotics determined by nutritional status of rotavirus-infected neonatal mice. J Pediatr Gastroenterol Nutr 55:299
Dias RS, Bambirra EA, Silva ME, Nicoli JR (1995) Protective effect of Saccharomyces boulardii against the cholera toxin in rats. Braz J Med Biol Res 28:323–325
Isolauri E, Kaila M, Arvola T, Majamaa H, Rantala I, Virtanen E, Arvilommi H (1993) Diet during rotavirus enteritis affects jejunal permeability to macromolecules in suckling rats. Pediatr Res 33:548–553
Gu’erin-Danan C, Meslin J-C, Chambard A, Charpilienne A, Relano P, Bouley C, Cohen J, Andrieux C (2001) Food supplementation with milk fermented by Lactobacillus casei DN-114 001 protects suckling rats from rotavirus-associated diarrhea. J Nutr 131:111–117
Zhang Z, Xiang Y, Li N, Wang B, Ai H, Wang X, Huang L, Zheng Y (2013) Protective effects of Lactobacillus rhamnosus GG against human rotavirus-induced diarrhoea in a neonatal mouse model. Pathog Dis 67:184–191
Zhou M, Yu H, Yin X, Sabour PM, Chen W, Gong J (2014) Lactobacillus zeae protects Caenorhabditis elegans from enterotoxigenic Escherichia coli-caused death by inhibiting enterotoxin gene expression of the pathogen. PLoS ONE 9, e89004
Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, Verkman AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin--induced intestinal fluid secretion. J Clin Invest 110:1651–1658
Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS (2004) Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 126:511–519
De La Fuente R, Namkung W, Mills A, Verkman AS (2008) Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel. Mol Pharmacol 73:758–768
Ko EA, Jin BJ, Namkung W, Ma T, Thiagarajah JR, Verkman AS (2014) Chloride channel inhibition by a red wine extract and a synthetic small molecule prevents rotaviral secretory diarrhoea in neonatal mice. Gut 63:1120–1129
Rufo PA, Merlin D, Riegler M, Ferguson-Maltzman MH, Dickinson BL, Brugnara C, Alper SL, Lencer WI (1997) The antifungal antibiotic, clotrimazole, inhibits chloride secretion by human intestinal T84 cells via blockade of distinct basolateral K+ conductances. Demonstration of efficacy in intact rabbit colon and in an in vivo mouse model of cholera. J Clin Invest 100:3111
Wulff H, Castle NA (2010) Therapeutic potential of KCa3. 1 blockers: recent advances and promising trends. Expert Rev Clin Pharmacol 3:385–396
Sonawane ND, Zhao D, Zegarra–Moran O, Galietta LJ, Verkman AS (2007) Lectin conjugates as potent, nonabsorbable CFTR inhibitors for reducing intestinal fluid secretion in cholera. Gastroenterology 132:1234–1244
Snyder DS, Tradtrantip L, Yao C, Kurth MJ, Verkman AS (2011) Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease. J Med Chem 54:5468–5477
Tradtrantip L, Sonawane ND, Namkung W, Verkman AS (2009) Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem 52:6447–6455
Geibel J, Sritharan K, Geibel R, Geibel P, Persing JS, Seeger A, Roepke TK, Deichstetter M, Prinz C, Cheng SX et al (2006) Calcium-sensing receptor abrogates secretagogue-induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction. Proc Natl Acad Sci USA 103:9390–9397
Jouret F, Wu J, Hull M, Rajendran V, Mayr B, Schofl C, Geibel J, Caplan MJ (2013) Activation of the Ca2+−sensing receptor induces deposition of tight junction components to the epithelial cell plasma membrane. J Cell Sci 126:5132–5142
Schulzke JD, Andres S, Amasheh M, Fromm A, Gunzel D (2011) Anti-diarrheal mechanism of the traditional remedy Uzara via reduction of active chloride secretion. PLoS ONE 6, e18107
Saito T, Miyake M, Toba M, Okamatsu H, Shimizu S, Noda M (2002) Inhibition by apple polyphenols of ADP-ribosyltransferase activity of cholera toxin and toxin-induced fluid accumulation in mice. Microbiol Immunol 46:249–255
Schuier M, Sies H, Illek B, Fischer H (2005) Cocoa-related flavonoids inhibit CFTR-mediated chloride transport across T84 human colon epithelia. J Nutr 135:2320–2325
Oi H, Matsuura D, Miyake M, Ueno M, Takai I, Yamamoto T, Kubo M, Moss J, Noda M (2002) Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation. Proc Natl Acad Sci USA 99:3042–3046
Becker PM, van der Meulen J, Jansman A, van Wikselaar PG (2012) In vitro inhibition of ETEC K88 adhesion by pea hulls and of LT enterotoxin binding by faba bean hulls. J Anim Physiol Anim Nutr 96:1121–1126
Namkung W, Thiagarajah JR, Phuan P-W, Verkman AS (2010) Inhibition of Ca2+−activated Cl-channels by gallotannins as a possible molecular basis for health benefits of red wine and green tea. FASEB J24:4178–4186
Morinaga N, Iwamaru Y, Yahiro K, Tagashira M, Moss J, Noda M (2005) Differential activities of plant polyphenols on the binding and internalization of cholera toxin in vero cells. J Biol Chem 280:23303–23309
Ataka K, Kuge T, Venkova K, Greenwood-Van Meerveld B (2003) Seirogan (wood creosote) inhibits stress-induced ion secretion in rat intestinal epithelium. Dig Dis Sci 48:1303–1309
Vel’azquez C, Correa-Basurto J, Garcia-Hernandez N, Barbosa E, Tesoro-Cruz E, Calzada S, Calzada F (2012) Anti-diarrheal activity of (−−)-Epicatechin from Chiranthodendron pentadactylon Larreat: Experimental and computational studies. J Ethnopharmacol 143:716–719
Chen J-C, Chang Y-S, Wu SL, Chao D-C, Chang C-S, Li C-C, Ho T-Y, Hsiang C-Y (2007) Inhibition of Escherichia coli heat-labile enterotoxin-induced diarrhea by Chaenomeles speciosa. J Ethnopharmacol 113:233–239
Iwami M, Shiina T, Hirayama H, Shima T, Takewaki T, Shimizu Y (2011) Inhibitory effects of zingerone, a pungent component of Zingiber officinale Roscoe, on colonic motility in rats. J Nat Med 65:89–94
Acknowledgments
The authors thank the Director of NDRI for supporting the work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
There was no funding available.
Conflict of interest
The author declared that they have no conflict of interest.
Ethical statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Anand, S., Mandal, S., Patil, P. et al. Pathogen-induced secretory diarrhea and its prevention. Eur J Clin Microbiol Infect Dis 35, 1721–1739 (2016). https://doi.org/10.1007/s10096-016-2726-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-016-2726-5